175
Participants
Start Date
March 15, 2025
Primary Completion Date
June 30, 2027
Study Completion Date
December 31, 2027
ripertamab
On Day 1 of the treatment period, an intravenous infusion of Ripertamab at a dose of 375 mg/m² body surface area will be administered.
Placebo
On Day 1 of the treatment period, an intravenous infusion of Placebo at a dose of 375 mg/m² body surface area will be administered.
Zhongming Qiu
OTHER